The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)
- PMID: 12450705
- DOI: 10.1016/s0264-410x(02)00449-8
The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)
Abstract
To further scientific progress of immunization safety, comparability of data from clinical trials and surveillance systems is essential. Comparability requires the availability of standardized case definitions for adverse events following immunization (AEFI) and guidelines for case determination, recording and data presentation.
Method: International collaborative working groups, consisting of professional volunteers from developed and developing countries, conduct systematic literature reviews to develop 50-100 AEFI definitions. Case definitions are finalized after a comment period by a reference group consisting of organizations concerned with immunization safety, and will be disseminated via the world-wide-web and other means for free world-wide use.
Results: Literature reviews yielded substantial diversity in data collection and presentation. We have developed standardized case definitions together with guidelines for use in clinical trials and surveillance systems.
Conclusions: Diversity in safety methods leads to considerable loss of scientific information. We have built the necessary international network of currently about 300 participants from patient care, public health, scientific, pharmaceutical, regulatory and professional organizations to develop and assess standardized AEFI case definitions and guidelines. Evaluation studies, global implementation, ongoing definition development and a continuously growing network will be essential for the success of the collaboration.
Similar articles
-
Safety reporting in developing country vaccine clinical trials-a systematic review.Vaccine. 2012 May 9;30(22):3255-65. doi: 10.1016/j.vaccine.2012.02.059. Epub 2012 Mar 7. Vaccine. 2012. PMID: 22406279 Review.
-
Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study.Vaccine. 2010 Jun 17;28(28):4487-98. doi: 10.1016/j.vaccine.2010.04.041. Epub 2010 Apr 29. Vaccine. 2010. PMID: 20434547
-
Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization.Vaccine. 2008 Nov 25;26(50):6349-60. doi: 10.1016/j.vaccine.2008.09.002. Epub 2008 Sep 19. Vaccine. 2008. PMID: 18805456
-
The development of standardized case definitions and guidelines for adverse events following immunization.Vaccine. 2007 Aug 1;25(31):5671-4. doi: 10.1016/j.vaccine.2007.02.063. Epub 2007 Mar 12. Vaccine. 2007. PMID: 17400339 No abstract available.
-
Reporting of vaccine safety data in publications: systematic review.Pharmacoepidemiol Drug Saf. 2005 Feb;14(2):101-6. doi: 10.1002/pds.979. Pharmacoepidemiol Drug Saf. 2005. PMID: 15386705 Review.
Cited by
-
Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study).BMJ Med. 2023 Mar 23;2(1):e000302. doi: 10.1136/bmjmed-2022-000302. eCollection 2023. BMJ Med. 2023. PMID: 37063238 Free PMC article.
-
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.Vaccine. 2023 Apr 6;41(15):2615-2629. doi: 10.1016/j.vaccine.2023.02.083. Epub 2023 Mar 3. Vaccine. 2023. PMID: 36925422 Free PMC article.
-
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273).Vaccine. 2022 Aug 19;40(35):5275-5293. doi: 10.1016/j.vaccine.2022.06.005. Epub 2022 Jun 9. Vaccine. 2022. PMID: 35753841 Free PMC article.
-
Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.Vaccine. 2022 Aug 19;40(35):5248-5262. doi: 10.1016/j.vaccine.2022.06.008. Epub 2022 Jun 14. Vaccine. 2022. PMID: 35715352 Free PMC article.
-
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for an inactivated viral vaccine against Chikungunya virus.Vaccine. 2022 Aug 19;40(35):5263-5274. doi: 10.1016/j.vaccine.2022.06.006. Epub 2022 Jun 15. Vaccine. 2022. PMID: 35715351 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical